• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British journal of psychiatry : >Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.
【24h】

Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.

机译：CHRNA7，CNR1和COMT在精神分裂症中的基因型效应：与烟草和大麻的相互作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Genetic variations might modify associations between schizophrenia and cannabis or tobacco use. AIMS: To examine whether variants within the cannabinoid receptor (CNR1) and alpha(7) nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use. We also examined a putative interaction between cannabis and Val(158)Met within the catechol-O-methyltransferase gene (COMT). METHOD: Genotype effects of CHRNA7 and CNR1were studied in a case-control sample of 750 individuals with schizophrenia and 688 controls, with interactions for these genes studied in small subsamples. A case-only design of 493 ofthe schizophrenia group was used to examine interactions between cannabis use and COMT. RESULTS: There was no evidence of association between schizophrenia and CNR1 (OR=0.97, 95% CI 0.82-1.13) or CHRNA7 (OR=1.07, 95% CI 0.77-1.49) genotypes, or of interactions between tobacco use and CHRNA7, or cannabis use and CNR1or COMT genotypes. CONCLUSIONS: Neither CNR1 nor CHRNA7 variation appears to alter the risk of schizophrenia. Furthermore, our results do not support the presence of different effects of cannabis use on schizophrenia according to variation within COMT.
机译：背景：遗传变异可能会改变精神分裂症与大麻或烟草使用之间的关联。目的：检查大麻素受体（CNR1）和α（7）烟碱样受体（CHRNA7）基因内的变异是否与精神分裂症有关，以及这些效应是否因大麻或烟草使用而异。我们还检查了儿茶酚-O-甲基转移酶基因（COMT）中大麻和Val（158）Met之间的推定相互作用。方法：在750例精神分裂症患者和688例对照的病例对照样本中研究了CHRNA7和CNR1的基因型效应，并在小样本中研究了这些基因的相互作用。精神分裂症组493的仅病例设计用于检查大麻使用与COMT之间的相互作用。结果：没有证据表明精神分裂症和CNR1（OR = 0.97，95％CI 0.82-1.13）或CHRNA7（OR = 1.07，95％CI 0.77-1.49）基因型之间存在关联，或吸烟与CHRNA7之间的相互作用，或大麻使用和CNR1或COMT基因型。结论：CNR1和CHRNA7变异均未改变精神分裂症的风险。此外，根据COMT中的变化，我们的结果不支持使用大麻对精神分裂症有不同的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号